Peripheral insulin-like growth factor 1 in bipolar disorder

Psychiatry Research

Volumn 250, Issue , 2017, Pages 30-34

  da Silva, Emily G ^a,b   Pfaffenseller, Bianca ^a,b   Walz, Julio ^b,c   Stertz, Laura ^d   Fries, Gabriel ^d   Rosa, Adriane R ^a,b   Magalhães, Pedro V ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Mestrado em Avaliacao de Impactos Ambientais em Mineracao Victor Barreto   (Brazil)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Bipolar disorder; IGF 1; Inflammation; Neurotrophins

Indexed keywords

GROWTH HORMONE; INSULIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR; HUMAN GROWTH HORMONE;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONING ASSESSMENT SHORT TEST; HAMILTON DEPRESSION RATING SCALE; HUMAN; INFLAMMATION; MALE; PROTEIN BLOOD LEVEL; YOUNG MANIA RATING SCALE; BLOOD; METABOLISM; MIDDLE AGED; REFERENCE VALUE;

ADULT; BIPOLAR DISORDER; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; REFERENCE VALUES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85010679740     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2017.01.061     Document Type: Article

References (48)

1. Aas, M., Henry, C., Andreassen, O.A., Bellivier, F., Melle, I., Etain, B., The role of childhood trauma in bipolar disorders. Int J. Bipolar Disord., 4, 2016, 2, 10.1186/s40345-015-0042-0.
2. Al-Delaimy, W.K., von Muhlen, D., Barrett-Connor, E., Insulinlike growth factor-1, insulinlike growth factor binding protein-1, and cognitive function in older men and women. J. Am. Geriatr. Soc. 57 (2009), 1441–1446, 10.1111/j.1532-5415.2009.02343.x.
3. Aleman, A., Torres-Alemán, I., Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog. Neurobiol. 89 (2009), 256–265, 10.1016/j.pneurobio.2009.07.008.
4. Arwert, L.I., Veltman, D.J., Deijen, J.B., van Dam, P.S., Delemarre-van deWaal, H.A., Drent, M.L., Growth hormone deficiency and memory functioning in adults visualized by functional magnetic resonance imaging. Neuroendocrinology 82 (2005), 32–40, 10.1159/000090123.
5. Bach, L.A., Insulin-like growth factor binding proteins 4-6. Best Pr. Res Clin. Endocrinol. Metab. 29 (2015), 713–722, 10.1016/j.beem.2015.06.002.
6. Benarroch, E.E., Insulin-like growth factors in the brain and their potential clinical implications. Neurology 79 (2012), 2148–2153, 10.1212/WNL.0b013e3182752eef.
7. Benbassat, C.A., Lazarus, D.D., Cichy, S.B., Evans, T.M., Moldawer, L.L., Lowry, S.F., Unterman, T.G., Interleukin-1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF alpha) regulate insulin-like growth factor binding protein-1 (IGFBP-1) levels and mRNA abundance in vivo and in vitro. Horm. Metab. Res. 31 (1999), 209–215.
8. Bezchlibnyk, Y.B., Xu, L., Wang, J.-F., Young, L.T., Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Res. 1147 (2007), 213–217, 10.1016/j.brainres.2007.01.147.
9. Bigornia, S.J., Farb, M.G., Mott, M.M., Hess, D.T., Carmine, B., Fiscale, A., Joseph, L., Apovian, C.M., Gokce, N., Relation of depot-specific adipose inflammation to insulin resistance in human obesity. Nutr. Diabetes, 2, 2012, e30, 10.1038/nutd.2012.3.
10. Bondy, C.A., Lee, W.H., Patterns of insulin-like growth factor and IGF receptor gene expression in the brain. Functional implications. Ann. N. Y. Acad. Sci. 692 (1993), 33–43.
11. Bücker, J., Fries, G.R., Kapczinski, F., Post, R.M., Yatham, L.N., Vianna, P., Bogo Chies, J.A., Gama, C.S., Magalhães, P.V., Aguiar, B.W., Pfaffenseller, B., Kauer-Sant'Anna, M., Brain-derived neurotrophic factor and inflammatory markers in school-aged children with early trauma. Acta Psychiatr. Scand. 131 (2015), 360–368, 10.1111/acps.12358.
12. Cacilhas, A.A., Magalhães, P.V., da, S., Ceresér, K.M., Walz, J.C., Weyne, F., Rosa, A.R., Vieta, E., Kapczinski, F., Validity of a short functioning test (FAST) in Brazilian outpatients with bipolar disorder. Value Health J. Int. Soc. Pharm. Outcomes Res. 12 (2009), 624–627, 10.1111/j.1524-4733.2008.00481.x.
13. Carro, E., Nuñez, A., Busiguina, S., Torres-Aleman, I., Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci. 20 (2000), 2926–2933.
14. Dávila, D., Torres-Aleman, I., Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol. Biol. Cell 19 (2008), 2014–2025, 10.1091/mbc.E07-08-0811.
15. Fan, J., Wojnar, M.M., Theodorakis, M., Lang, C.H., Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1. Am. J. Physiol. 270 (1996), R621–R629.
16. Fernandez, A.M., Torres-Alemán, I., The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 13 (2012), 225–239, 10.1038/nrn3209.
17. Frey, B.N., Andreazza, A.C., Houenou, J., Jamain, S., Goldstein, B.I., Frye, M.A., Leboyer, M., Berk, M., Malhi, G.S., Lopez-Jaramillo, C., Taylor, V.H., Dodd, S., Frangou, S., Hall, G.B., Fernandes, B.S., Kauer-Sant'Anna, M., Yatham, L.N., Kapczinski, F., Young, L.T., biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar disorders biomarkers task force. Aust. N. Z. J. Psychiatry 47 (2013), 321–332, 10.1177/0004867413478217.
18. Gama, C.S., Kunz, M., Magalhães, P.V.S., Kapczinski, F., Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev. Bras. Psiquiatr. São Paulo Braz. 1999:35 (2013), 70–74.
19. Gatenby, V.K., Kearney, M.T., The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. Expert Opin. Ther. Targets 14 (2010), 1333–1342, 10.1517/14728222.2010.528930.
20. Grande, I., Magalhães, P.V., Kunz, M., Vieta, E., Kapczinski, F., Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol. Behav. 106 (2012), 46–50, 10.1016/j.physbeh.2011.10.029.
21. Guy, M., Nursing care study: splenectomy. Nurs. Mirror Midwives J. 143 (1976), 59–60.
22. Jansen, K., Cardoso, T.A., Fries, G.R., Branco, J.C., Silva, R.A., Kauer-Sant'Anna, M., Kapczinski, F., Magalhaes, P.V., Childhood trauma, family history, and their association with mood disorders in early adulthood. Acta Psychiatr. Scand., 2016, 10.1111/acps.12551.
23. Kapczinski, F., Dal-Pizzol, F., Teixeira, A.L., Magalhaes, P.V.S., Kauer-Sant'Anna, M., Klamt, F., Moreira, J.C.F., de Bittencourt Pasquali, M.A., Fries, G.R., Quevedo, J., Gama, C.S., Post, R., Peripheral biomarkers and illness activity in bipolar disorder. J. Psychiatr. Res., 45, 2011, 156–161, 10.1016/j.jpsychires.2010.05.015.
24. Kapczinski, F., Dal-Pizzol, F., Teixeira, A.L., Magalhaes, P.V.S., Kauer-Sant'Anna, M., Klamt, F., Pasquali, M.A., de, B., Quevedo, J., Gama, C.S., Post, R., A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol. Psychiatry 15 (2010), 784–786, 10.1038/mp.2009.112.
25. Kapczinski, F., Magalhães, P.V.S., Balanzá-Martinez, V., Dias, V.V., Frangou, S., Gama, C.S., Gonzalez-Pinto, A., Grande, I., Ha, K., Kauer-Sant'Anna, M., Kunz, M., Kupka, R., Leboyer, M., Lopez-Jaramillo, C., Post, R.M., Rybakowski, J.K., Scott, J., Strejilevitch, S., Tohen, M., Vazquez, G., Yatham, L., Vieta, E., Berk, M., Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr. Scand. 130 (2014), 354–363, 10.1111/acps.12305.
26. Kauer-Sant'Anna, M., Kapczinski, F., Andreazza, A.C., Bond, D.J., Lam, R.W., Young, L.T., Yatham, L.N., Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. Off. Sci. J. Coll. Int. Neuropsychopharmacol. CINP 12 (2009), 447–458, 10.1017/S1461145708009310.
27. Kern, P.A., Ranganathan, S., Li, C., Wood, L., Ranganathan, G., Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280 (2001), E745–E751.
28. Kim, Y.K., Na, K.S., Hwang, J.A., Yoon, H.K., Lee, H.J., Hahn, S.W., Lee, B.H., Jung, H.Y., High insulin-like growth factor-1 in patients with bipolar I disorder: a trait marker?. J. Affect. Disord. 151 (2013), 738–743, 10.1016/j.jad.2013.07.041.
29. Lee, Y.I., Han, Y.J., Lee, S.Y., Lee, Y.I., Park, S.K., Park, Y.J., Moon, H.B., Shin, J.H., Lee, J.H., Activation of insulin-like growth factor II signaling by mutant type p53: physiological implications for potentiation of IGF-II signaling by p53 mutant 249. Mol. Cell. Endocrinol. 203 (2003), 51–63.
30. Lelbach, A., Scharf, J.G., Ramadori, G., Regulation of insulin-like growth factor-I and of insulin-like growth factor binding protein-1, −3 and −4 in cocultures of rat hepatocytes and Kupffer cells by interleukin-6. J. Hepatol. 35 (2001), 558–567.
31. Liu, X., Zhang, T., He, S., Hong, B., Chen, Z., Peng, D., Wu, Y., Wen, H., Lin, Z., Fang, Y., Jiang, K., Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Res. 218 (2014), 54–60, 10.1016/j.psychres.2014.03.042.
32. Magalhães, P.V.S., Jansen, K., Pinheiro, R.T., Klamt, F., Teixeira, A.L., da Silva, R.A., Kapczinski, F., Systemic toxicity in early-stage mood disorders. J. Psychiatr. Res. 45 (2011), 1407–1409, 10.1016/j.jpsychires.2011.05.008.
33. Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R., O'Neill, C., Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31 (2010), 224–243, 10.1016/j.neurobiolaging.2008.04.002.
34. Niblock, M.M., Brunso-Bechtold, J.K., Riddle, D.R., Insulin-like growth factor I stimulates dendritic growth in primary somatosensory cortex. J. Neurosci. Off. J. Soc. Neurosci. 20 (2000), 4165–4176.
35. Nyberg, F., Hallberg, M., Growth hormone and cognitive function. Nat. Rev. Endocrinol. 9 (2013), 357–365, 10.1038/nrendo.2013.78.
36. O'Connor, J.C., McCusker, R.H., Strle, K., Johnson, R.W., Dantzer, R., Kelley, K.W., Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell. Immunol. 252 (2008), 91–110, 10.1016/j.cellimm.2007.09.010.
37. Palomino, A., González-Pinto, A., Martinez-Cengotitabengoa, M., Ruiz de Azua, S., Alberich, S., Mosquera, F., Matute, C., Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 44 (2013), 29–33, 10.1016/j.pnpbp.2013.01.008.
38. Russo, V.C., Gluckman, P.D., Feldman, E.L., Werther, G.A., The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. 26 (2005), 916–943, 10.1210/er.2004-0024.
39. Spielman, L.J., Little, J.P., Klegeris, A., Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J. Neuroimmunol. 273 (2014), 8–21, 10.1016/j.jneuroim.2014.06.004.
40. Squassina, A., Costa, M., Congiu, D., Manchia, M., Angius, A., Deiana, V., Ardau, R., Chillotti, C., Severino, G., Calza, S., Del Zompo, M., Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacol. Res. 73 (2013), 1–7, 10.1016/j.phrs.2013.04.004.
41. Stertz, L., Magalhães, P.V.S., Kapczinski, F., Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr. Opin. Psychiatry 26 (2013), 19–26, 10.1097/YCO.0b013e32835aa4b4.
42. Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., Arvanitakis, Z., Schneider, J.A., Wolf, B.A., Bennett, D.A., Trojanowski, J.Q., Arnold, S.E., Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Investig. 122 (2012), 1316–1338, 10.1172/JCI59903.
43. Torres Aleman, I., Insulin-like growth factor-1 and central neurodegenerative diseases. Endocrinol. Metab. Clin. N. Am. 41 (2012), 395–408, 10.1016/j.ecl.2012.04.016.
44. Trejo, J.L., Carro, E., Garcia-Galloway, E., Torres-Aleman, I., Role of insulin-like growth factor I signaling in neurodegenerative diseases. J. Mol. Med. Berl. Ger. 82 (2004), 156–162, 10.1007/s00109-003-0499-7.
45. Valverde, A.M., Benito, M., Lorenzo, M., The brown adipose cell: a model for understanding the molecular mechanisms of insulin resistance. Acta Physiol. Scand. 183 (2005), 59–73, 10.1111/j.1365-201X.2004.01384.x.
46. Venters, H.D., Tang, Q., Liu, Q., VanHoy, R.W., Dantzer, R., Kelley, K.W., A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. Proc. Natl. Acad. Sci. Usa. 96 (1999), 9879–9884.
47. Wyss-Coray, T., Mucke, L., Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35 (2002), 419–432.
48. Yatham, L.N., Kennedy, S.H., Parikh, S.V., Schaffer, A., Beaulieu, S., Alda, M., O'Donovan, C., Macqueen, G., McIntyre, R.S., Sharma, V., Ravindran, A., Young, L.T., Milev, R., Bond, D.J., Frey, B.N., Goldstein, B.I., Lafer, B., Birmaher, B., Ha, K., Nolen, W.A., Berk, M., Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 15 (2013), 1–44, 10.1111/bdi.12025.